Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Belcher, G ^a   Hubner R ^a   George, M ^a   Elmfeldt, D ^b   Lunde, H ^b  

^a Takeda Pharma GmbH   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Candesartan cilexetil; Drug safety; Hypertension; Review

Indexed keywords

AMLODIPINE; CANDESARTAN HEXETIL; HYDROCHLOROTHIAZIDE; LIPID;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; BLOOD GLUCOSE MONITORING; BRONCHITIS; CLINICAL TRIAL; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; ELECTROCARDIOGRAM; FEMALE; FLU LIKE SYNDROME; GLUCOSE INTOLERANCE; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REBOUND; RHINITIS; RISK FACTOR; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030657582     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Grueninger UJ, Strasser T (eds). Educating the hypertensive patient. J Hum Hypertens 1990; 4 (Suppl 1): 1.
2. Schulman N et al. Correlates of attendance and compliance in the hypertension detection and follow-up program. Controlled Clin Trials 1982; 3: 13-27.
3. Croog SH et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.
4. Black DM et al, for the SHEP Pilot Research Group. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. J Geront 1987; 42: 552-557.
5. Neaton JD et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713-724.
6. Jones JK et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 1995; 11: 293-295.
7. Belz GG et al. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S45-S47.
8. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997; 11 (Suppl 2): S9-S17.
9. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl 2): S27-S28.
10. Elmfeldt D, Hübner R, George M, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose-dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
11. McInnes GT et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl 2): S75-S80.
12. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11 (Suppl 2): S81-S83.
13. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S69-S73.
14. Philipp T, Letzel H. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate essential hypertension. J Hum Hypertens 1997; 11 (Suppl 2): S67-S68.
15. Plouin P-F. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997; 11 (Suppl 2): S65-S66.
16. Farsang C et al. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10 (4 Pt 2): 80A.
17. Perish RC, Miller LJ. Adverse effects of an angiotensin converting enzyme (ACE) inhibitor. Drug Safety 1992; 7: 14-31.
18. Fyhrquist F. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989; 226: 257-260.
19. Fridman K, Andersson OK, Wysocki M, Friberg P. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 1997; 11 (Suppl 2): S43-S44.
20. de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl 2): S37-S42.
21. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
22. O'Brien AAJ, Bulpitt CJ. Hypertensive disease. In: Speight TM, Holford NHG (eds). Avery's Drug Treatment, 4th Edn. Adis International Ltd: Auckland, 1997, pp 897-932.